论文部分内容阅读
协同调控收缩是平滑肌的关键属性,其收缩功能正常,有助于维持机体整体健康;如发生功能失调,会增加疾病发病率和病死率。蛋白激酶C加强的磷酸酶抑制剂17(protein kinase C-potentiated phosphatase inhibitorof 17 ku,CPI-17)是磷酸化依赖的肌球蛋白轻链磷酸酶(myosin light chain phosphatase,MLCP)抑制蛋白,其可增加肌球蛋白轻链(20 ku myosin light chain,MLC20)磷酸化水平,增强平滑肌收缩。CPI-17功能受多种蛋白激酶和磷酸酶的调节。近年研究发现,在病理生理条件下,其表达和活性上调或下降与子宫、血管、气管、胃肠道等多种平滑肌功能密切相关。针对CPI-17对平滑肌细胞的调节作用及机制的深入研究有助于进一步阐明平滑肌功能障碍相关疾病及其功能失调的发病机制,并为其临床治疗提供新思路。
Collaborative regulation of contraction is a key property of smooth muscle, and its systolic function is normal, helps to maintain the overall health of the body; such as dysfunction, will increase disease morbidity and mortality. Protein kinase C-potentiated phosphatase inhibitor of 17 ku (CPI-17) is a phosphorylation-dependent myosin light chain phosphatase (MLCP) inhibitory protein which can Increase myosin light chain (20 ku myosin light chain, MLC20) phosphorylation levels, enhance smooth muscle contraction. CPI-17 function is regulated by a variety of protein kinases and phosphatases. Recent studies have found that in the pathophysiological conditions, its expression and activity up or down and the uterus, blood vessels, trachea, gastrointestinal tract and other smooth muscle function are closely related. In order to further clarify the pathogenesis of smooth muscle dysfunction-related diseases and their dysfunction, aiming at the regulatory effect of CPI-17 on smooth muscle cells and its mechanism, and to provide new ideas for its clinical treatment.